OrPro Therapeutics

OrPro Therapeutics is a preclinical stage Johnson & Johnson JLABS alumni company addressing large unmet medical needs in respiratory, ophthalmology and oncology with a novel cell-protective biologic drug platform.

OrPro Therapeutics in the News

OrPro Therapeutics acquires $2.15M in Grant funding from the DoD for potential COVID and Influenza drug

July 19, 2022

Meet OrPro Therapeutics

OrPro Therapeutics is a privately-held preclinical-stage company developing a non-systemic biologic drug platform for treatment of diseases of the lung and other epithelial surfaces characterized by chronic infection, inflammation and obstructive mucus. The company’s core technology was licensed exclusively from National Jewish Health (NJH, Denver, CO), the leading US respiratory hospital, with key patent-protected improvements (the Theradux® platform) developed internally. OrPro is pursuing a platform/product strategy for in-house commercialization with selected out-licensing.

Why is your company the best option to solve the problem you're solving?

Secreted human proteins have proven to be some of the most successful blockbuster therapeutics because of their unusually high safety and efficacy in addressing large unmet medical needs. Our broad platform-in-a-product strategy, advanced manufacturing and formulation, and strong intellectual property create opportunities for early exits and multiple shots on goal vs. proven disease targets.

What else do you want us to know?

We were recently awarded a $2.147M grant from the prestigious Congressionally Directed Medical Research Programs administered by the US Department of Defense. This will fund key development milestones for our lead candidate ORP100S as a treatment for acute viral lung injury, including in vitro and in vivo evaluation in models of COVID and severe influenza. We are partnered with Mount Sinai to test our drug in their 3-D human lung organoid system and are also working on an oncology program in collaboration with Duke University.